Abstract: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic dissolved in a solution comprising an extractive solvent, e.g., DMSO or NMP, in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered as a regional anesthesia to a subject to anesthetize a portion the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, or mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.

Abstract: Methods are provided for performing fluid catalytic cracking (and/or other hydrothermal processing for cracking of hydrocarbons) on a feedstock containing hydrocarbons in the presence of a catalyst that includes zeolite Beta that is stabilized toward hydrothermal conditions. The hydrothermally stabilized zeolite Beta (including any of the various polymorphs) corresponds to zeolite Beta that is formed without the use of an organic structure directing agent, and that is further stabilized by addition of one or more stabilizers, such as lanthanide series elements or phosphorus.

Abstract: The disclosure is related to EMM-31 materials, processes, and uses of the same as well as reagents used in the preparation of the EMM-31 materials, process and intermediates for preparing these reagents.

Abstract: The disclosure is related to EMM-37 materials, processes of making, and uses of the same as well as structure directing agents useful for the preparation of the EMM-37 materials, processes and intermediates for making such structure directing agents.

Abstract: The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.

Abstract: A molecular sieve having the framework structure of ZSM-5 is described comprising crystals having an external surface area in excess of 100 m2/g (as determined by the t-plot method for nitrogen physisorption) and a unique X-ray diffraction pattern.

Abstract: The zeolite UTD-1 may be formed under hydrothermal synthesis conditions using a directing agent that does not include a metal atom therein. Methods for synthesizing the zeolite UTD-1 may comprise: combining at least a silicon atom source and a directing agent having a structure of in an aqueous medium; forming the zeolite in the aqueous medium under hydrothermal synthesis conditions, such that the zeolite has a framework silicate with a cationic portion of the directing agent occluded within pores or channels of the framework silicate; and isolating the zeolite from the aqueous medium. The zeolite has a powder x-ray diffraction pattern with at least the following 2?scattering angles: 6.0±0.12, 7.6±0.1, 14.66±0.15, 19.7±0.15, 21.27±0.15, 22.13±0.15, 22.61±0.15, and 24.42±0.10 for a borosilicate form zeolite, or 6.0±0.12, 7.6±0.15, 14.55±0.15, 19.64±0.15, 21.01±0.20, 21.90±0.20, 22.34±0.20, and 24.38 ±0.20 for an aluminosilicate form zeolite.

Abstract: A novel synthetic crystalline material, EMM-28, can be synthesized in the presence of an organic structure directing agent (Q) selected from one or more of the following dications: EMM-28 may be used in organic compound conversion reactions and sorptive processes.

Abstract: The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.

Abstract: In a process for separating one or more 3,3?-, 3,4?- and 4,4?-dimethyl biphenyl isomers, a feed comprising the isomers is contacted with a zeolite adsorbent which contains one or more metal cations in the +1 or +2 oxidation states. Separation processes for each of the 3,3?-, 3,4?- and 4,4?-dimethyl biphenyl isomers is provided.

Abstract: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered to the subject to anesthetize the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon, and mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.

Abstract: This disclosure relates to the preparation of diphenyl compounds, especially dimethylbiphenyl compounds, in which there is one methyl group on each ring, and their oxidized analogues. These compounds, and particularly alkylated biphenyl compounds and biphenylcarboxylic acids, alcohols and esters, are useful intermediates in the production of a variety of commercially valuable products, including polyesters and plasticizers for PVC and other polymer compositions.

Abstract: A process is disclosed for producing small crystal, high surface area crystalline materials having the MFI and/or MEL framework-type, designated as EMM-30, using as a structure directing agent tetrabutylammonium cations and/or tetrabutylphosphonium cations, or 1,5-bis(N-tributylammonium)pentane dications, and/or 1,6-bis(N-tributylammonium)hexane dications. The compositions made according to that process, as well as the various dication compositions themselves, are also disclosed.

Abstract: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic dissolved in a solution comprising an extractive solvent, e.g., DMSO or NMP, in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered as a regional anesthesia to a subject to anesthetize a portion the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, or mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.

Abstract: The disclosure is related to EMM-37 materials, processes of making, and uses of the same as well as structure directing agents useful for the preparation of the EMM-37 materials, processes and intermediates for making such structure directing agents.

Abstract: The present invention relates to the synthesis of succinimides, in particular to a method for the synthesis of a succinimide compound, comprising the step of reacting an alkyne, with carbon monoxide and ammonia or an amine, in the presence of an iron catalyst, wherein the reaction is carried out in an amine liquid phase and/or in the absence of an ether solvent. The succinimides may be reduced to quaternary ammonium cations which may be used as structure directing agents in the synthesis of molecular sieves.

Abstract: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered to the subject to anesthetize the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon, and mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.

Abstract: A novel synthetic crystalline material, EMM-28, can be synthesized in the presence of an organic structure directing agent (Q) selected from one or more of the following dications: EMM-28 may be used in organic compound conversion reactions and sorptive processes.

Abstract: The disclosure is related to EMM-31 materials, processes, and uses of the same as well as reagents used in the preparation of the EMM-31 materials, process and intermediates for preparing these reagents.

Abstract: A molecular sieve having the framework structure of ZSM-5 is produced using one or more of 1,4-bis(N-pentylpyrrolidinium)butane dications, 1,5-bis(N-pentylpyrrolidinium)pentane dications, and 1,6-bis(N-pentylpyrrolidinium)hexane dications as a structure directing agent.